This ADC product is comprised of an anti-TACSTD2 monoclonal antibody (clone 7E6) conjugated via a PEG6 linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
Antibody clone #
7E6
ADC Target
Name
TACSTD2
Alternative Names
TACSTD2; tumor-associated calcium signal transducer 2; EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1; epithelial glycoprotein-1; cell surface glycoprotein TROP2; cell surface glycoprotein Trop-2; pancreatic carcinoma marker protein GA7331; pancreatic ca
This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.
ADC Antibody
Overview
Humanized Anti-TACSTD2 antibody, clone # 7E6
Clone #
7E6
Species Reactivity
Human
ADC Linker
Name
PEG6 ((Propylene Glycol)-6-propionyl)
Description
Polyethylene glycol (PEG) is a polyether compound with many applications from industrial manufacturing to medicine. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), depending on its molecular weight.
ADC payload drug
Name
MMAD (monomethyl auristatin D)
Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.